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Background: The BODE index has been shown to predictmortality in COPD. The index includes the
6minwalking test as themeasureofexercisecapacity.The incremental shuttlewalking test (ISWT)
isanalternativemeasureofexercisecapacitywhichcanbeusedtoprescribeexerciseandhasbeen
found to correlate well with peak VO2. The objective of the study was to evaluate the incorpora-
tion of the ISWTwithin the BODE index (named the i-BODE) to predict mortality in COPD.
Methods: Datawas analysed from633patientswithCOPDattendingpulmonary rehabilitationover
an 11 year period, andmortality determined aminimumof one year on from initial assessment. An
i-BODE score was calculated using ISWT(m) then Cox regression analysis evaluated the capacity of
the index to predict risk of death.
Results: BMI, ISWT (m), MRC dyspnoea score, pack years and age were all significantly associated
with mortality. Cox regression revealed the i-BODE index was an independent and significant
predictor ofmortality (hazard ratio 1.27 (CI 1.17e1.35), p< 0.001) andKaplanMeier survival anal-
ysis showed each quartile increase in severity in i-BODE score was significantly associated with
increased mortality (p < 0.001 by log rank test).
Conclusion: Wehave found the i-BODE index to be an independent predictor ofmortality in COPD,
even when other strong predictors such as age and pack years are adjusted for. We conclude that
the ISWT can be successfully substituted for the 6MWT as an alternative measure of exercise
capacity within the BODE index.
ª 2011 Elsevier Ltd. All rights reserved.HRC Rehabilitation Theme, University Hospitals of Leicester NHS Trust, Glenfield Hospital,
2563652; fax: þ44 116 2502743.
uhl-tr.nhs.uk (J.E.A. Williams).
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outpatient based pulmonary rehabilitation (PR) service andChronic obstructive pulmonary disease (COPD) is
a complex, multi-system disease primarily characterised by
increased breathlessness, reduced physical activity and
progressive muscle deconditioning. Assessment of lung
function, principally the degree of airflow obstruction (and
in particular the forced expiratory volume in 1 s FEV1), has
been widely used in the categorisation of severity of COPD.1
However, it is recognised that lung function parameters
such as FEV1 are poor predictors of morbidity and mortality
2
and a number of multi-factorial grading scales have
therefore been developed in an attempt to better assess
severity, disability and prognosis in COPD.3e7
The BODE Index, reported in 2004 by Celli et al,3 has
been shown to predict mortality,8 risk of hospitalisation9
and exacerbation10 as well as being predictive of a range
of health related quality of life outcomes.11e15 The BODE
Index is comprised of four components: B (Body Mass
Index), O (airflow obstruction as measured by FEV1 % pre-
dicted), D (functional dyspnoea as measured by the modi-
fied Medical Research Council (MRC) dyspnoea scale) and E
(exercise capacity as measured by the 6 min walking test
(6MWT)). The index was initially modelled using the four
factors identified in a cohort of COPD patients that best
predicted risk of death. They then went on to validate
prospectively the BODE Index in a second cohort of patients
with COPD and found that the BODE Index was a better
predictor of mortality than FEV1 alone.
Exercise capacity has been shown to be a very strong
predictor of mortality, whether measured by sophisticated
cardiopulmonary exercise testing (CPET) or simpler-to-
perform field exercise tests such as the 6MWT or the incre-
mental shuttlewalking test (ISWT).16e20 Themeasurement of
peak oxygen uptake (peak VO2) by CPET is considered to be
the ‘gold standard’ measurement of exercise capacity and
the BODE index has previously been modified to incorporate
a value of peak VO2 within the index.
21,22 The ISWT is an
alternative field exercise test to the 6MWT23 which is
employed in a number of clinical and research environments
andhasbeen showntobehighly correlated topeakVO2.
24 The
main difference between the two field tests are that the
6MWT is a self-paced time-limited testwhereas the ISWT is an
externally paced test where a patient walks to a symptom-
limited maximum. Performance on the 6MWT and the ISWT
have been shown to be significantly related to one another23
but it is not known if the ISWTwould have similar predictive
properties within the BODE index. The aim of this study
thereforewas toevaluatewhether amodificationof theBODE
index calculated using the ISWT as an alternative measure of
exercise capacity to the 6MWT (named the i-BODE), could be
a discriminatory and independent predictor of mortality in
patients with COPD.Methods
Patients
We completed a retrospective analysis of data which had
been collected from patients who had been referred to ourhad attended an initial assessment at Leicester Hospitals
during the period from the beginning of 1998 to the end of
2008. Patients were predominately referred by a respiratory
physician and we included all patients who had a clinical
diagnosis of COPD. Patients were categorised using the four
stage spirometric classification of disease severity as rec-
ommended by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD).1 The majority of patients were classi-
fied as being Stage II to IV of disease severity (FEV1 < 80%
predicted or an FEV1/Forced Vital Capacity (FVC) ratio of
<70%). A small number of patients were categorised as being
in GOLD stage I i.e. they had an FEV1 80% but these patients
were included in the analysis as they were symptomatic and
had been referred to pulmonary rehabilitation.
Patients gave consent for their data to be recorded in
a specific pulmonary rehabilitation database. Baseline data
collectedat the timeof initial assessment for PR includedany
significant co-morbidities, demographic details, oxygen use,
pack years smoked, height and weight in order to calculate
BMI, spirometry (FEV1, FVC performed as per established
standards2 and the 5 point MRC dyspnoea scale (0e5 scale).
All patients carried out the incremental shuttle walking test
(ISWT) which is part of the standard initial assessment for PR
at our institution. The ISWT is a standardised and objective
measure of exercise capacity where the patient walks
incrementally faster to a series of timed beeps until they
reach a symptom-limited maximal distance, measured in
metres. The patient performs two tests, 30 min apart with
the highest value of the two walks recorded.23
In order to maximise the number of complete datasets
available for analysis, any missing data for FEV1 or height
and weight was obtained where possible from our respira-
tory physiology department database (recorded in the same
year as the PR assessment). Patients were excluded from
the final analysis if they did not have recorded (or it was not
possible to obtain at a later date) data relating to the four
components of the BODE index i.e. Body Mass Index (BMI),
FEV1, Medical Research Council (MRC) dyspnoea grade and
exercise tolerance (ISWT). Other exclusion criteria included
significant musculo-skeletal, neurological, cardiac or
cognitive problems.
Once all eligible patients had been identified on the PR
database, the main hospital records database was then
searched to ascertain survival status and censored at March
1st 2010. If patients had died then date of death was noted
and the time in days from initial PR assessment to death
was calculated. There was a minimum of one year follow up
from time of initial assessment.Identification of factors predicting mortality
An extended multi-variate Cox proportional hazards model
was used to identify which factors significantly predicted
mortality. The variables included in themodel were: gender,
age (entered as a time-dependent variable), pack years
smoked, FEV1, FVC, BMI, MRC dyspnoea grade and ISWT
distance walked. This was done to enable us to account for
any additional factors not already included in the BODE index
which were found to also significantly predict mortality in
this cohort of patients. We did not eliminate any factors
Table 2 Patient characteristics for the total COPD group
and the BODE subgroup.
Variable (mean
(SD) unless stated)
Total group
n Z 1615
BODE subgroup
n Z 633
Male/female 1014/601 379/254
Age (years) 68.4 (9.0) 68.9 (9.0)
FEV1 (litres) 1.04 (0.5) 1.11 (0.5)
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of the original BODE index intact.
Allocation of points for the i-BODE index
In order to allocate points for the i-BODE index, it was first
necessary to assign cut off values for the ISWT. How the cut
off values for the 6MWT were assigned in the original BODE
validation is not clear.3 In the development of the i-BODE,
data for the ISWT distance walked (m) for the total COPD
cohort was divided into four equal parts (quartiles). The cut
off values for each quartile and allocation of points for the
i-BODE are displayed in Table 1. Patients received points
ranging from 0 (the least disabled patients who walked
more than 250 m on the ISWT) to 3 (the most disabled
patients who walked 80 m or less on the ISWT).
An i-BODE score was then calculated for each patient
(using the values for each component as they were at the
time of initial PR assessment) and using the original BODE
weightings and scoring system for the FEV1% predicted and
BMI. We replaced distance walked on the ISWT for the
6MWT distance with the allocation of points as described
above (Table 1). We also substituted the original MRC
dyspnoea grading scale which ranges from 1 to 5 for the
modified MRC scale (0e4) as used by Celli et al.3
Evaluation of the i-BODE index to predict death
To evaluate the capacity of the i-BODE index to predict risk
of death, we performed extended Cox proportional hazards
regression analysis. We estimated the hazard ratio, 95%
confidence intervals and p value for the i-BODE score,
including an adjustment for any additional significant
prognostic factors which had been previously identified.
The i-BODE index scores were then stratified into quartiles,
survival time was estimated using Kaplan Meier analysis and
the log rank test performed to compare mortality between
patients across the i-BODE quartiles. Continuous variables
are presented as mean (SD) unless otherwise stated.
P < 0.05 was considered to be statistically significant. All
analysis was done using Predictive Analytics Software
(PASW) Statistics version 18 (formerly SPSS).
Results
Patient characteristics
1615 patients with a diagnosis of COPD were initially iden-
tified on the database. All the patients had been assessedTable 1 Variables and point allocation used for the
computation of the i-BODE index.
Variable 0 points 1 point 2 points 3 points
FEV1% predicted 65 50e64 36e49 35
Distance walked
on ISWT (m)
250 150e249 80e149 <80
MRC Dyspnoea
Grade
1e2 3 4 5
BMI >21 21under similar clinical conditions i.e. prior to starting
pulmonary rehabilitation. However 982 patients had to be
excluded from the analysis as it was not possible to
compute an i-BODE score due to missing data of one or
more BODE components. This left 633 patients with full
data points for all four BODE components i.e. BMI (height
and weight), FEV1, MRC grade and exercise tolerance
(ISWT). Table 2 shows the comparison of the patient
demographics and outcome measures for all the COPD
subjects on the database and for those subjects with full
BODE data. Independent t tests revealed that there were
some significant differences between the BODE subgroup
and those patients with missing data, in terms of FEV1, FVC
and ISWT distance (Table 3).
In the BODE subgroup, 24% of patients were classified as
having very severe COPD (stage IV), 39% had severe COPD
(stage III), 32% had moderate COPD (stage II) and 5% had
mild disease (Stage I)(GOLD stage classification1). Table 2
shows the mean values for ISWT distance walked for
patients in each GOLD stage. Overall all-cause mortality for
the BODE subgroup was 10.5% at one year (n Z 47).
Mortality at two and five years was 24.7% (n Z 98) and
57.1% respectively (nZ 189). Mean length of follow up was
32 months.
Identification of factors predicting mortality
Multi-variate Cox proportional hazards analysis revealed
that in our cohort of patients, three of the four original
BODE factors were significantly associated with all-cause
mortality: BMI (p < 0.001), MRC dyspnoea grade (pZ 0.014)
and exercise capacity (ISWT) (p < 0.001). FEV1 did not
reach significance (p Z 0.16). We also found age and pack
years smoked to be significantly associated with increased
risk of mortality (p  0.001)(Table 4).
Evaluation of the i-BODE index to predict mortality
The i-BODE score was significantly lower at the time of
initial assessment (i.e. better) for survivors than forFVC (litres) 2.39 (2.9) 2.60 (3.4)
FEV1 % predicted 44.6 (19.8) 45.7 (20.1)
FEV1/FVC ratio 46.1 (16.2) 45.4 (17.7)
Pack years smoked 41.6 (26.9) 42.6 (23.1)
MRC grade
(median and range)
4 (1e5) 4 (1e5)
ISWT (m) e total group 175.7 (122.4) 203.8 (129.7)
GOLD Stage I 188.2 (147.0) 219.4 (146.3)
GOLD Stage II 198.7 (134.5) 209.8 (137.8)
GOLD Stage III 198.6 (125.6) 207.5 (126.7)
GOLD Stage IV 168.6 (116.3) 186.00 (118.6)
Table 3 Patient Characteristics for the BODE subgroup
and subjects with missing data.
Variable (mean
(SD) unless stated)
Subjects with
missing data
n Z 982
BODE subgroup
n Z 633
p value
Male/female 637/345 379/254
Age (years) 68.1 (9.0) 68.9 (9.0) 0.08
FEV1 (litres) 1.00 (0.5) 1.10 (0.5) 0.001*
FVC (litres) 2.25 (2.4) 2.59 (3.4) 0.03*
FEV1 % predicted 42.3 (19.0) 45.5 (20.1) 0.03*
FEV1/FVC ratio 46.7 (15.2) 45.4 (17.7) 0.15
Pack years smoked 40.7 (29.7) 42.7 (23.1) 0.21
MRC grade
(median and
range)
4 (1e5) 4 (1e5)
ISWT (m) 156.7 (113.4) 203.8 (129.7) 0.001*
*Independent t test, between group difference significant at
p < 0.05.
Table 5 Cox proportional hazards model showing the
i-BODE score as an independent predictor of mortality,
including the adjustment for age and pack years smoked.
Predictor B Wald
chi2
Hazard ratio
(95% CI)
P value
i-BODE score 0.24 44.3 1.27 (1.18e1.36) <0.001
Age 0.00 20.5 1.00 (1.00e1.00) <0.001
Pack years
smoked
0.01 9.6 1.00 (1.00e1.02) 0.002
Overall model fit -2 log likelihood 1736.3, chi2 88.2.
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year time points from assessment. Mean i-BODE scores for
survivors and patients that had died within one year were:
4.7þ/2.3 vs. 6.5þ/1.7, independent t test p < 0.001
and 4.7þ/2.3 vs. 6.2þ/2.0, p < 0.001 for patients who
had died by two years. Even at five years there was
a significant difference at initial assessment between
i-BODE scores for survivors and those that had subsequently
died: 4.8þ/2.2 vs. 5.9þ/2.2, p < 0.001. The i-BODE
index was found to be a significant predictor of death, even
after adjustment was made for the additional prognostic
factors identified, age and pack years smoked (Table 5).
The adjusted hazard ratio for death per one point increase
in the i-BODE score was 1.27 (confidence interval 1.18 to
1.36, p < 0.001).
Kaplan Meier survival analysis
The cut-offs for the four i-BODE quartiles were as follows:
quartile one e 0 to 2 points, quartiles two e 3 to 4 points,
quartile three e 5 to 6 points, quartile four e 7 to 10 points.
The Kaplan Meier analysis of survival (Fig. 1) showed that
each quartile increase in the score was significantlyTable 4 Cox proportional hazards model of independent
predictors of death in COPD.
Predictor B Wald
chi2
Hazard Ratio
(95% CI)
p value
Age (years) 0.05 29.8 1.00 (1.00e1.01) <0.001
Gender 0.15 0.66 1.16 (0.81e1.67) 0.42
Pack years
smoked
0.01 15.9 1.01 (1.00e1.02) <0.001
FEV1 (L) 0.28 2.0 0.76 (0.5e1.11) 0.16
FVC (L) 0.02 2.5 1.02 (0.99e1.05) 0.12
BMI (Kg/m2) 0.07 21.3 0.93 (0.90e0.96) <0.001
MRC grade 0.21 6.1 1.25 (1.04e1.45) 0.014
ISWT (m) 0.00 13.5 1.00 (0.99e1.00) <0.001
Overall model fit -2 log likelihood 1488.1, chi2 91.4.associated with increased mortality (p < 0.001 by the log
rank test). Patients in the highest i-BODE quartile had
a mortality rate of 83.3% at 60 months.
Discussion
This study has shown that a composite scoring system
incorporating the ISWT with BMI, airflow obstruction and
MRC dyspnoea score (the i-BODE index) is a discriminatory
predictor of mortality in a cohort of COPD patients referred
for pulmonary rehabilitation. We found that the i-BODE
index was a statistically significant and independent
predictor of death with every one point increase in i-BODE
score being associated with a 1.27 increased risk of death.
In a similar size of cohort to that originally used in the
BODE study, we identified several factors that predicted
mortality. We found that three of the four original BODE
factors: BMI, MRC dyspnoea score and exercise capacity
(ISWT distance walked) were independent significant
predictors of mortality as well as age and pack years
smoked. These findings are in line with other recently
published multi-factorial indices such as the DOSE index7
which includes smoking status (as well as dyspnoea,
airflow obstruction and exacerbation frequency) or the ADO
index4 which includes age (plus dyspnoea and airflowFigure 1 Kaplan Meier survival curves for the four quartiles
of the i-BODE index.
Quartile 1 is a score of 0 to 2, quartile 2 is a score of 3 to 4,
quartile 3 is a score of 5 to 6 and quartile 4 is a score of 7 to 10.
Survival differed significantly among the 4 groups: p<0.0001 by
the log rank test.
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adjusting for age and pack years smoked, the i-BODE index
independently predicted mortality with a similar hazard
ratio to that reported in the original BODE paper. In line
with other observations of the relatively poor prognostic
value of FEV1 in terms of morbidity and mortality in COPD,
FEV1 did not significantly predict mortality in our
population.
Since its publication in 2004, the BODE index has been
widely used in numerous studies to assess a range of
outcomes including exacerbation frequency, health related
quality of life and depression, risk of hospitalisation and
mortality.9e15,25e29 The original BODE index was modelled
on the predictors of death in the 25 patients who had died
by one year from assessment out of the total group of 207.
In our study we found that there were 47 deaths by one
year, 98 by two years and 189 deaths out of the 262 patients
who had been assessed five years previously (which repre-
sents a 58% mortality rate). Significantly lower (i.e., better)
i-BODE scores at the time of PR assessment were found for
those patients who were still alive one, two or five years
later than for those that had subsequently died. Similarly,
Kaplan Meier analysis of survival revealed that each quar-
tile increase in the i-BODE score was significantly associ-
ated with increased mortality.
The BODE index has been previously modified to incor-
porate a value of peak VO2 as a replacement for the
6MWT.21 The authors observed an excellent correlation
between the conventional BODE index and the modified
index incorporating a value of peak VO2, expressed either in
millilitres per minute per kilogram or as a percentage of the
predicted value. Our rationale for investigating whether
the BODE index could be modified to include the ISWT as an
alternative measure of exercise capacity in the BODE index
model was based on a number of factors.
During the development of the ISWT, Singh et al found
therewas a significant relationship between distancewalked
in the 6MWT and the ISWT.23 The ISWT was also found to
correlate well with measures of peak VO2 observed during
cardiopulmonary exercise testing (CPET).23,24 Turner et al
examined peak heart rate, dyspnoea and oxygen desatura-
tion response in patients with COPD carrying out the 6MWT,
ISWTand CPETand observed no significant differences in any
variable among the three tests.30 Casas et al31 have also re-
ported a comparison of the 6MWTwith three clinical exercise
protocols in random order: a stair climbing test, incremental
cycling test and the ISWT. They found that oxygen uptake
(VO2) reached a plateau after the third minute of the 6MWT
while VO2 increased up to the end of the test in the other
three exercise protocols. There was an abrupt rise in VO2
during stair climbing whereas there was a steady increase in
VO2 during the incremental cycling and walking tests.
As this study was a retrospective observational analysis
of data from patients who attended for a clinical PR
assessment, we were not able to directly compare patients’
performance on the 6MWT and the ISWT. However, given
the similar physiological responses observed between the
tests30,31 we hypothesized that the 6MWT and the ISWT
were likely to predict mortality in a similar way within the
BODE index. There have been no direct comparisons in the
literature between the two tests in the evaluation of
mortality in COPD although in a study of patients withchronic heart failure, the ISWT was found to predict event-
free survival at one year better than the 6MWT.32
While spirometry should always be obtained to diagnose
airflow obstruction in patients with respiratory symptoms,33
the recent NICE guidelines2 have highlighted the poor
prognostic value of relying on spirometry alone to assess
disability and morbidity in COPD. The guidelines recom-
mend the use of a multi-dimensional index such as the
BODE where a more accurate prognosis is considered
necessary. Although indices such as the ADO4 or DOSE7 have
the practical advantage of not requiring an exercise test,
numerous studies have shown the strong predictive value of
including a measure of exercise capacity to assess prognosis
where feasible.16,19,20,27,33e36 In a study evaluating
predictors of mortality following outpatient PR, Geradi
et al37 found that the post PR measure of the 12 min
walking test was the most significant variable related to
prognosis out of a range of outcomes. The ISWT has
recently been found to be a strong and independent
predictor of survival in a population of COPD patients who
were being screened for pulmonary rehabilitation.20 Ring-
baek et al identified a threshold value of 170 m that best
predicted mortality, with patients walking less than 170 m
having a 2.84 fold increased risk of dying over those who
were able to walk more than 170 m. In fact walking less
than 170 m on the ISWT had the highest relative risk of
dying out of a range of variables such as age over 75 years,
having a BMI less than 24, a smoking history of over 50 pack
years, being on long term oxygen therapy or being a current
smoker. Previous work by Cote et al22 have identified
a walking distance of less than 350 m as being the threshold
to discriminate survival for the 6MWT.
There are limitations to this study. The study was
a retrospective analysis of a clinical pulmonary rehabilita-
tion database with the attendant frustrations of missing
data. However the number of patients on the database and
the long time frame it covers has enabled us to study the
mortality of a large number of patients over a longer period
of follow up than might easily be achieved under prospec-
tive study conditions. The i-BODE score was calculated as it
would have been at the time of initial PR assessment and
then mortality status for the entire dataset was censored at
a set time point. Another potential limitation might be that
because all the patients had been referred to a hospital
based pulmonary rehabilitation service, with the majority
of patients falling into the more severe end of the COPD
spectrum, this may make the results less applicable to
those patients with more mild disease who are being
managed in primary care.
This study has evaluated mortality in a large cohort of
patients with COPD over a long time period and shown that
the i-BODE index is an independent predictor of mortality,
even when other strong predictors such as age and pack
years smoked are accounted for. We conclude that the
ISWT can be used as an alternative measure of exercise
capacity within the BODE index and the conceptual
framework of the index be preserved. For practitioners of
the ISWT, the development of the i-BODE index will extend
the range of clinicians and researchers who will be able to
calculate a BODE score (as recommended by NICE).2 In
turn, this may help to improve the prediction of prognostic
outcomes for patients with COPD and enable the targeting
Development of the i-BODE 395of resources to those who are the more vulnerable and
higher risk patients.
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